Danaher completes acquisition of Masimo, expanding its diagnostics portfolio with advanced patient monitoring tech.

Danaher Corporation has finalized its acquisition of Masimo Corporation, a specialist in pulse oximetry and patient monitoring solutions used mainly in acute care. Masimo will operate as a standalone subsidiary under Danaher's Diagnostics segment, enhancing Danaher's product offerings with its advanced sensor and AI technology. Masimo's stock has stopped trading on Nasdaq following the deal. Danaher expects to update its 2026 financial guidance to reflect Masimo's contribution after the second quarter earnings report, although no significant impact is expected in Q2 2026.